The method of producing immunogen from tuberculosis mycobacteria (BCG)
Higher educational establishment (Ukraine) proposes the project for producing immunogen from tuberculosis mycobacteria (BCG). The immunogen is appropriated for production of polyclonal antibodies in high titer and can be used for laboratory diagnostics of tuberculosis. Due to its high efficasy the method allows to reduce the period of antibodies production 2-20 times. It is harmless as compared with analogues. The organization looking for investors for continuation of the research effort.
Domestic technology for producing immunogen from tuberculosis mycobacteria, first of all, to produce immunogen from vaccine strain (BCG) Myсobaсterium bovis.
The technology for producing immunogen from vaccine strain (BCG) Myсobaсterium bovis is used in medicine and immunology instead of producing immunogen from pathogenic mycobacteria strains. Immunogenicity of immunogen is sufficient to produce polyclonal antisera with specific antibodies in high titer.
Technology seller has enough research effort experience concerning producing immunogen from tuberculosis mycobacteria (confirmation – 1 ukrainian patent).
Інновації і переваги пропозиції:
Adoption of new technology allows to provide castomers with tools for producing immunogen from vaccine strain (BCG) Myсobaсterium bovis by simplified method, including attenuation and passaging of bacteria with the use of growth stimulator and culture medium BCG for growth acceleration to produce of sufficient number of mycobacteria in safe working conditions.
The technology is easy-to-fulfilment, not requiring special experience. It allows to cut down the expenses on personal safety and to reduce timetable 2-20 times as compared with analogues.
Додаткова інформація (технічні подробиці)
Specification of immunogen from vaccine strain (BCG) Myсobaсterium bovis provides personal safety without special safety precautions, allows avoid of prolonged culturing and passaging of bacteria and the use of growth stimulator results in growth acceleration and immunogen producing 2-20 times faster than that with the use of prototype.